Drug Profile
ABH 001
Alternative Names: ABH-001; Dermagraft; Human fibroblast-derived dermal substituteLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Shire
- Developer Takeda
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epidermolysis bullosa